StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Trading Up 0.6 %
Galmed Pharmaceuticals stock opened at $0.39 on Thursday. The stock has a fifty day moving average price of $0.36 and a 200 day moving average price of $0.38. Galmed Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $7.80. The firm has a market capitalization of $1.96 million, a P/E ratio of -0.12 and a beta of 0.83.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- Retail Stocks Investing, Explained
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Options Trading – Understanding Strike Price
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
